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Abstract
Background
Clinical practice guidelines have traditionally recommended blood pressure treatment
based primarily on blood pressure thresholds. In contrast, using predicted cardiovascular
risk has been advocated as a more effective strategy to guide treatment decisions for car-
diovascular disease (CVD) prevention. We aimed to compare outcomes from a blood pres-
sure-lowering treatment strategy based on predicted cardiovascular risk with one based on
systolic blood pressure (SBP) level.
Methods and findings
We used individual participant data from the Blood Pressure Lowering Treatment Trialists’
Collaboration (BPLTTC) from 1995 to 2013. Trials randomly assigned participants to either
blood pressure-lowering drugs versus placebo or more intensive versus less intensive blood
pressure-lowering regimens. We estimated 5-y risk of CVD events using a multivariable
Weibull model previously developed in this dataset. We compared the two strategies at spe-
cific SBP thresholds and across the spectrum of risk and blood pressure levels studied in
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External researchers may suggest new research
BPLTTC trials. The primary outcome was number of CVD events avoided per persons
treated. We included data from 11 trials (47,872 participants). During a median of 4.0 y of fol-
low-up, 3,566 participants (7.5%) experienced a major cardiovascular event. Areas under
the curve comparing the two treatment strategies throughout the range of possible thresh-
olds for CVD risk and SBP demonstrated that, on average, a greater number of CVD events
would be avoided for a given number of persons treated with the CVD risk strategy com-
pared with the SBP strategy (area under the curve 0.71 [95% confidence interval (CI) 0.70–
0.72] for the CVD risk strategy versus 0.54 [95% CI 0.53–0.55] for the SBP strategy). Com-
pared with treating everyone with SBP 150 mmHg, a CVD risk strategy would require
treatment of 29% (95% CI 26%–31%) fewer persons to prevent the same number of events
or would prevent 16% (95% CI 14%–18%) more events for the same number of persons
treated. Compared with treating everyone with SBP 140 mmHg, a CVD risk strategy
would require treatment of 3.8% (95% CI 12.5% fewer to 7.2% more) fewer persons to pre-
vent the same number of events or would prevent 3.1% (95% CI 1.5%–5.0%) more events
for the same number of persons treated, although the former estimate was not statistically
significant. In subgroup analyses, the CVD risk strategy did not appear to be more beneficial
than the SBP strategy in patients with diabetes mellitus or established CVD.
Conclusions
A blood pressure-lowering treatment strategy based on predicted cardiovascular risk is
more effective than one based on blood pressure levels alone across a range of thresholds.
These results support using cardiovascular risk assessment to guide blood pressure treat-
ment decision-making in moderate- to high-risk individuals, particularly for primary
prevention.
Author summary
Why was this study done?
• Hypertension treatment guidelines have traditionally relied primarily on blood pressure
levels to guide use of blood pressure-lowering medications.
• Cardiovascular disease (CVD) prevention guidelines, like those for cholesterol manage-
ment, instead advocate for multivariable CVD risk assessment to guide treatment
decisions.
• Simulation studies have modeled the benefits of using CVD risk to guide blood pressure
management, but there has not been a direct comparison using clinical trial data with
actual outcome events.
What did the researchers do and find?
• We included individual participant data from 11 trials (48,872 participants) of partici-
pants in the Blood Pressure Treatment Trialists’ Collaboration (BPLTTC).
Blood pressure treatment based on risk versus blood pressure
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• We estimated the number of CVD events avoided for a given number of persons treated
using CVD risk to determine blood pressure-lowering treatment compared with using
systolic blood pressure (SBP) level.
• We compared the two treatment strategies at specific blood pressure thresholds and
across the spectrum of CVD risk and SBP levels studied in the BPLTTC.
• We demonstrated that a treatment strategy based on predicted CVD risk could prevent
more events and require treatment of fewer persons than one based on SBP level.
• Using predicted CVD risk was particularly beneficial in the primary prevention
subgroup.
What do these findings mean?
• These results support using cardiovascular risk assessment to guide blood pressure
treatment decisions in moderate- to high-risk individuals.
• The results challenge current paradigms in hypertension management and highlight the
merits of using predicted CVD risk to guide blood pressure-lowering treatment
intensity.
Introduction
Clinical practice guidelines for hypertension treatment have traditionally relied primarily on
blood pressure levels to guide use of blood pressure-lowering medications [1–4]. However,
single risk factor levels, like blood pressure, incompletely capture risk. Furthermore, blood
pressure-lowering medications provide a fairly consistent relative risk reduction across a range
of blood pressure levels, leading to large variations in absolute benefit from blood pressure
treatment observed among individuals [5–7].
In contrast to hypertension guidelines, cholesterol treatment guidelines have moved away
from single risk factor levels to guide treatment and instead advocate for multivariable absolute
cardiovascular disease (CVD) risk assessment to guide treatment decision-making [8–10].
Updates to some cholesterol guidelines have moved even further by eliminating cholesterol
goals altogether and identifying CVD risk thresholds to guide clinician–patient risk discus-
sions about statin initiation in primary prevention [8,10].
Recently, an analysis from the Blood Pressure Lowering Treatment Trialists’ Collaboration
(BPLTTC) demonstrated similar relative risk reductions from blood pressure-lowering medi-
cations across a range of predicted risk strata with correspondingly greater absolute risk reduc-
tions in those with higher predicted risk [11]. Those results provide support for the role of
CVD risk assessment in guiding blood pressure-lowering treatment decisions. Although simu-
lation studies have modeled the benefits of a CVD risk strategy for blood pressure-lowering
treatment compared with traditional hypertension guidelines [12,13], to date, there has not
been a direct comparison of the two strategies using clinical trial data with actual outcome
events. Such evidence is needed to move CVD risk-based treatment strategies into clinical
practice.
Blood pressure treatment based on risk versus blood pressure
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Cardiology; ACE, angiotensin-converting enzyme;
ACEI, angiotensin-converting enzyme inhibitor;
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Evaluation; AHA, American Heart Association;
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Individual participant data from trials in the BPLTTC provide an ideal opportunity to compare
these two treatment strategies across a range of possible treatment thresholds in a group of indi-
viduals who were randomly assigned to blood pressure-lowering therapy in a clinical trial setting.
In this study, we sought to compare outcomes using a treatment strategy based on predicted CVD
risk (CVD risk strategy) with one based on systolic blood pressure (SBP) level (SBP strategy).
Methods
This analysis followed a prespecified protocol that was presented to the BPLTTC Steering com-
mittee in April 2013.
Trial eligibility and comparisons
This meta-analysis includes individual participant data from the BPLTTC from 1995 to 2013.
Trials were eligible for this analysis if they met the original inclusion criteria for the Collabora-
tion overviews and were part of the subset of trials that randomly allocated participants to
blood pressure-lowering drug or placebo or to a more intensive versus less intensive blood
pressure drug treatment regimen [14]. Eligible trials were also required to have a minimum of
1,000 patient years of planned follow-up in each randomized group and to have not presented
their main results before the Collaboration protocol was finalized in July 1995 [14]. For this
analysis, we analysed data from all eligible trials that provided sufficient information to enable
absolute CVD risk estimation.
We included the following treatment comparisons: angiotensin-converting enzyme (ACE)
inhibitors versus placebo; calcium channel blockers versus placebo; diuretics versus placebo;
and more intensive versus less intensive blood pressure-lowering regimens (regardless of drug
class). We combined these comparisons to maximize statistical power, since prior analyses
have demonstrated that most of the treatment effects were dependent on the amount of blood
pressure reduction achieved with few drug-specific effects [15].
Outcomes
We analyzed outcomes prespecified in the original BPLTTC protocol [14]. Our primary out-
come was total major CVD events, defined as a composite of stroke (nonfatal stroke or death
from cerebrovascular disease), coronary heart disease (nonfatal myocardial infarction or death
from coronary heart disease, including sudden death), heart failure (causing death or resulting
in admission to hospital), or CVD death.
Cardiovascular risk estimation
We used a multivariable Weibull model previously developed in this dataset from the placebo
groups. This model uses age, sex, body mass index, systolic and diastolic blood pressure
(DBP), prior blood pressure-lowering treatment, smoking status, diabetes mellitus status, and
history of CVD to estimate 5-y CVD risk. Details of the derivation and validation of this
model have been previously published [11].
Cardiovascular events avoided by treatment
To estimate the number of CVD events avoided by the CVD risk and SBP strategies, we ranked
all eligible participants by decreasing levels of baseline CVD risk and then by decreasing levels
of baseline SBP. Next, we considered a potential treatment threshold for each percentile of
CVD risk or SBP observed in the dataset. For each strategy, we assumed that all participants
with a level above a given threshold would be treated and everyone below would be untreated.
Blood pressure treatment based on risk versus blood pressure
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We then noted the number of persons above the threshold (“N treated”) and the Kaplan-Meier
estimated 5-y risks in the control groups above the threshold (“untreated 5-y risk”) at each per-
centile for each treatment strategy. In the subgroup of participants above the threshold, we cal-
culated the relative risk reduction from blood pressure-lowering therapy. For that purpose, we
used a one-step meta-analysis approach, fitting Weibull models with shared frailty for each trial,
thereby preserving the randomized structure of the trials [16]. To estimate the risk among the
treated (“treated 5-y risk”), we applied the obtained hazard ratios to the Kaplan–Meier 5-y risk
among control group participants above the threshold using the following formula: treated 5-y
risk = 1 − exp(hazard ratio  ln(1 − untreated 5-y risk)). We thereafter applied this to the total
number of persons above the threshold to calculate the number of events avoided with 5 y of
treatment: avoided events = n treated  (untreated 5-y risk − treated 5-y risk)).
The number of events avoided was graphically presented against the number and propor-
tion of treated persons. We then calculated the areas under the curves to estimate treatment
effectiveness (i.e., number of events avoided per persons treated) for each strategy, where
greater area reflects more events avoided per persons treated. Areas were calculated as integrals
using the trapezoidal rule and were expressed as the ratio of the obtained area to the maximum
possible area (maximum number of cardiovascular events avoided multiplied by the maximum
number of persons treated); treatment given at random to half the sample without consider-
ation of any treatment thresholds corresponding to an area of 0.5. We used bias-corrected 95%
bootstrap estimates from 10,000 repetitions to generate confidence intervals (CIs). We also cal-
culated numbers needed to treat for 5 y to avoid 1 cardiovascular event as 1/(number of events
avoided/number of treated persons for 5 y) at each threshold for each treatment strategy.
Secondary analyses
We evaluated the expected outcomes of each treatment strategy in subgroups based on pres-
ence or absence of previous blood pressure-lowering treatment, diabetes mellitus, and prevalent
CVD. The risk equation was well calibrated in all subgroups (S1 Fig). In a 2-stage meta-analysis
combining estimates in complementary pairs of subgroups, heterogeneity of results between
subgroups was assessed using I2 with corresponding 95% CIs. To determine if any differences
in cardiovascular events avoided were related to differences in magnitude of SBP reduction, we
quantified mean observed SBP reduction with blood pressure-lowering treatment using a
mixed-effects generalized linear model with the participant as the unit of analysis and a random
intercept for trial. Using these estimates, we standardized hazard ratios for each threshold and
for each treatment strategy to a 5 mmHg SBP reduction. Given the strong effect of age on 5-y
predicted CVD risk, we performed a sensitivity analysis comparing the CVD risk strategy and
SBP strategy with an age-based treatment strategy. For the age-based strategy, we ranked all eli-
gible participants by decreasing levels of age in a manner similar to what was done for baseline
SBP in the SBP strategy. Lastly, in a subsample without previous CVD, we performed a sensitiv-
ity analysis using the Framingham total CVD risk equation [17]. We recalibrated the published
equation to the observed survival rates and risk factor levels (means and proportions) in the
BPLTTC dataset, substituting body mass index when trials were missing lipid values.
We used Stata version 14 (Stata Corporation, College Station, TX, United States of Amer-
ica) for all analyses.
Results
Baseline characteristics
We included 11 trials consisting of 47,872 participants (35,671 participants without prevalent
CVD) in our analysis (some trials were factorial or included more than two groups) (S5 Fig)
Blood pressure treatment based on risk versus blood pressure
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[18–28]. Pooled baseline characteristics of participants are shown in Table 1. Mean systolic
and DBP differences between the active/more intense treatment versus placebo/less intense
treatment were 5.7/3.2 mmHg (95% CIs 5.5–6.0 mmHg and 3.0–3.3 mmHg, respectively).
Baseline characteristics and achieved blood pressure reduction by trial are included in Table 2
and S1 Table.
Cardiovascular events avoided with treatment
There were 3,566 (7.5%) participants who experienced an incident CVD event during a
median follow-up of 4.0 y (IQR 1.0, S2 Table). We estimated the number of CVD events
avoided over 5 y per person treated according to a CVD risk strategy compared with an SBP
strategy (Fig 1). The CVD risk strategy would result in a greater number of events avoided
per person treated compared with the SBP strategy. Similarly, for a given number of cardio-
vascular events avoided, a smaller proportion of the sample is treated using a CVD risk
strategy compared with the SBP strategy. Areas under the curve comparing the two treat-
ment strategies throughout the range of possible thresholds for CVD risk and SBP demon-
strated that, on average, a greater number of CVD events would be avoided for a given
number of persons treated with the CVD risk strategy compared with the SBP strategy (area
under the curve 0.71 [95% CI 0.70–0.72] for the CVD risk strategy versus 0.54 [95% CI
0.53–0.55] for the SBP strategy) (Fig 1).
Table 1. Baseline characteristics of participants from the BPLTTC (n = 47,872).
Characteristics Active/more intensive blood pressure-lowering
treatment
Placebo/less intensive blood pressure-lowering
treatment
Total
Participants, n 21,021 26,851 47,872
Mean age, y (SD) 65.7 (9.7) 64.7 (9.3) 65.2 (9.5)
Women, n (percentage) 9,614 (46) 12,298 (46) 21,912
(46)
BMI, kg/m2 (SD) 27.6 (4.8) 27.8 (4.8) 27.7 (4.8)
Mean SBP, mmHg (SD) 158 (22) 161 (21) 160 (21)
Mean DBP, mmHg (SD) 91 (13) 94 (13) 93 (13)
Mean total cholesterol, mmol/L (SD) 5.5 (1.5) 5.7 (1.4) 5.6 (1.5)
Mean HDL cholesterol, mmol/L (SD) 1.4 (0.6) 1.4 (0.6) 1.4 (0.6)
Previous antihypertensive treatment, n
(percentage)
11,977 (57) 15,073 (56) 27,050
(57)
Current smoking, n (percentage) 3,031 (14) 4,069 (15) 7,100 (15)
Diabetes mellitus, n (percentage) 8,048 (38) 8,225 (31) 16,273
(34)
Previous CVD, n (percentage) 6,051 (29) 6,150 (23) 12,201
(25)
Data obtained from participants in ABCD3_H, ABCD3_N, ADVANCE, BENEDICT1&2, HOT, HYVET, PART2, PREVENT, PROGRESS, SCAT, and SYST-EUR [18–
28]. Numbers of patients (n) are unbalanced because participants in some trials were not randomly assigned in a 1:1 ratio. To convert from mmol/L to mg/dL for total
cholesterol and HDL cholesterol, divide by 0.0259.
Abbreviations: ABCD, Appropriate Blood Pressure Control in Diabetics; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation; BMI, body mass index; BENEDICT; Bergamo Nephrologic Diabetes Complications Trial; BPLTTC, Blood Pressure Lowering Treatment
Trialists’ Collaboration; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOT, Hypertension Optimal Treatment; HYVET,
Hypertension in the Very Elderly Trial; PART2, Prevention of Atherosclerosis with Ramipril; PREVENT, Prospective Randomized Evaluation of the Vascular Effects of
Norvasc Trial; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; SCAT, Simvastatin/Enalapril Coronary Atherosclerosis Trial; SBP, systolic blood
pressure; SYST-EUR, Systolic Hypertension in Europe.
https://doi.org/10.1371/journal.pmed.1002538.t001
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The number needed to treat for 5 y to prevent 1 CVD event was lower with the CVD risk
strategy across a broad range of thresholds until overlapping with the SBP strategy at the 80th
percentile treatment rate (Fig 2). Hence, the CVD risk strategy was superior to the SBP strategy
in terms of identifying the persons with the highest absolute treatment benefit across a broad
range of plausible treatment thresholds.
More specifically, we selected three commonly proposed SBP treatment thresholds for
direct comparison with the CVD risk strategy (Tables 3 and 4). Compared with treatment at
an SBP threshold of 150 mmHg, a CVD risk threshold would require the treatment of 29%
(95% CI 26%–31%) fewer individuals to prevent the same number of CVD events (Table 3).
Alternatively, it could prevent 16% (95% CI 14%–18%) more CVD events for the same
number of persons treated (Table 4). Similarly, compared with an SBP threshold of 160
mmHg, using a CVD risk threshold would require treatment of 35% (95% CI 50%–24%)
fewer persons to prevent the same number of CVD events, or it could prevent 38% (95% CI
29%–40%) more CVD events for the same number of treated persons. Results at an SBP
threshold of 140 mmHg were imprecise due to the nature of our comparisons. At this
threshold, the CVD risk strategy would prevent 3% (95% CI 1.5%–5%) more CVD events
for the same number of persons treated and require 3.8% fewer (12.5% fewer to 7.2% more)
persons to be treated for the same number of events prevented, although this result was not
statistically significant.
Fig 1. Effects of CVD risk and SBP treatment strategies on absolute number of cardiovascular events prevented
over 5 y. Expected cardiovascular events avoided over 5 y of treatment as a function of number of persons and
proportion of sample treated using a CVD risk strategy (in green) and an SBP strategy (in red). Numbers associated
with each curve represent the specific CVD risk level (percentage 5-y CVD risk) or SBP (mmHg) at the treatment
threshold. Areas under the curve are expressed as the ratio of the obtained area to the maximum possible area
(maximum number of cardiovascular events avoided multiplied by the maximum number of participants treated) with
bias-corrected 95% bootstrap CIs from 10,000 repetitions in parentheses. Larger areas represent more events avoided
per persons treated. CI, confidence interval, CVD, cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.g001
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Fig 2. Numbers needed to treat for 5 y to avoid 1 cardiovascular event according to CVD risk and SBP treatment
strategies. Numbers needed to treat for 5 y to avoid 1 cardiovascular event as a function of number of persons and
proportion of sample treated using a CVD risk strategy (in green) and an SBP strategy (in red). Numbers associated
with each curve represent the specific CVD risk level (percentage 5-y CVD risk) or SBP (mmHg) at the treatment
threshold. CVD, cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.g002
Table 3. Persons needed to treat to avoid the same number of cardiovascular events over 5 y using selected SBP
thresholds and corresponding CVD risk thresholds. The BPLTTC (n = 47,872).
SBP threshold
140 mmHg 150 mmHg 160 mmHg
Persons and proportions treated using an SBP
threshold
n 39,231 (39,231
to 39,344)
33,891 (33,551
to 34,460)
27,039 (26,245
to 27,882)
percentage 81.9 (81.9 to
82.2)
70.8 (70.1 to
72.0)
56.5 (54.8 to
58.2)
Persons and proportions treated using a CVD risk
threshold selected to avoid the same number of
cardiovascular events
n 37,730 (34,343
to 42,073)
24,225 (23,743
to 25,660)
17,484 (14,108
to 21,333)
percentage 78.8 (71.7 to
87.9)
50.6 (49.6 to
53.6)
36.5 (29.5 to
44.6)
Difference in persons and relative difference in
proportions treated using SBP and CVD risk
thresholds selected to avoid the same number of
cardiovascular events
n −1,501
(−4,888 to
+2,842)
−9,667
(−10,717 to
−8,504)
−9,556
(−13,095 to
−6,603)
percentage −3.8 (−12.5 to
+7.2)
−28.5 (−31.1 to
−25.6)
−35.3 (−49.9 to
−24.2)
Estimates with 10,000 repetitions bias-corrected bootstrap with 95% CIs in parentheses. Negative sign represents
smaller proportion or lesser number. Positive sign represents bigger proportion or greater number.
Abbreviations: BPLTTC, Blood Pressure Lowering Treatment Trialists’ Collaboration; CI, confidence interval; CVD,
cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.t003
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Secondary analyses
Results were similar in subgroups with and without prior blood pressure-lowering medication
use, without diabetes mellitus, and without prevalent CVD (Fig 3). For those with baseline dia-
betes mellitus, the CVD risk strategy did not appear to be superior, while for those with prior
CVD, the SBP strategy appeared to be best (Fig 3).
Mean achieved SBP reductions and observed relative risk reductions for both the SBP strat-
egy and CVD risk strategy were similar across the range of possible CVD risk and SBP thresh-
olds (Fig 4 and Fig 5).
Results were similar for analyses standardized to a 5-mmHg SBP reduction (S2 Fig and S3
Fig), but differences were smaller. Furthermore, analyses comparing the two treatment strate-
gies with an age-based treatment strategy confirmed that the CVD risk strategy remained
superior in terms of events avoided per person treated compared with the SBP strategy (differ-
ence in areas under the curves 0.17 [95% CI 0.15–0.19]) and age-based strategy (difference in
areas under the curves 0.13 [95% CI 0.09–0.14]) (S4 Fig).
For analyses using the Framingham total CVD risk equation, a greater number of CVD
events would be avoided for a given number of persons treated with the CVD risk strategy
compared with the SBP strategy (area under the curve 0.66 [95% CI 0.65–0.72] for CVD risk
strategy versus 0.59 [95% CI 0.57–0.61] for the SBP strategy), although differences were smaller
than in analyses using the internally derived risk prediction equation.
Discussion
This analysis of nearly 50,000 persons studied in clinical trials demonstrated that a blood pres-
sure-lowering treatment strategy based on predicted CVD risk could prevent more events for
the same number of persons treated compared with a strategy based on SBP levels. The benefit
of the CVD risk strategy was particularly evident at higher SBP thresholds and for persons
without prevalent CVD or diabetes mellitus.
The superiority of the CVD risk strategy relative to the SBP strategy can be explained by
recent lessons from blood pressure epidemiology. First, the relative treatment benefit from
blood pressure-lowering medications is fairly consistent across different blood pressure levels,
Table 4. Cardiovascular events avoided over 5 y for the same number of persons treated using selected SBP
thresholds and corresponding CVD risk thresholds. The BPLTTC (n = 47,872).
SBP threshold
140 mmHg 150 mmHg 160 mmHg
n = 39,231 n = 33,891 n = 27,039
CVD events avoided using an SBP threshold n 821 (819 to
821)
698 (692 to
716)
557 (544 to
599)
CVD events avoided using a CVD risk threshold
selected to achieve the same number of persons
treated
n 847 (833 to
860)
809 (795 to
822)
767 (755 to
776)
Difference and relative difference in CVD events
avoided using SBP and CVD risk thresholds selected
to achieve the same number of persons treated
n +26 (+12 to
+41)
+111 (+97 to
+127)
+210 (175 to
222)
percentage +3.1 (+1.5 to
+5.0)
+15.8 (+13.7 to
+18.3)
+37.6 (+28.8 to
+40.2)
Estimates with 10,000 repetitions bias-corrected bootstrap with 95% CIs in parentheses. Negative sign represents
smaller proportion or lesser number. Positive sign represents greater number.
Abbreviations: BPLTTC, Blood Pressure Lowering Treatment Trialists’ Collaboration; CI, confidence interval; CVD,
cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.t004
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including nonhypertensive levels [6,7]. Second, the absolute risk of an individual at a given
blood pressure level can vary as much as 20-fold based on the presence of other vascular risk
factors such as age, sex, dyslipidemia, and diabetes mellitus [5,29]. Third, a previous meta-
analysis of individual participant data from the BPLTTC has shown that the relative benefit
from blood pressure-lowering treatment is similar across risk strata and that, therefore, the
absolute benefit from blood pressure-lowering treatment is greater in those with higher risk
[11]. Therefore, the expected absolute risk reduction achieved with blood pressure-lowering
treatment is better determined by the combination of risk factors contributing to CVD risk
rather than an isolated blood pressure level. In the present study, we quantified the benefits of
such a risk-based strategy and determined which groups of patients might experience those
benefits.
Indirect comparisons of CVD risk and SBP treatment strategies have previously been per-
formed using observational cohorts and modeled treatment effects. These analyses suggest that
treatment strategies based on absolute risk could prevent more cardiovascular events, save
more quality-adjusted life-years, use fewer medications, and lower overall costs compared
with treatment based on blood pressure level [12,13,30,31]. Our results confirm, quantify, and
extend these findings in a large group of persons who actually received blood pressure-lower-
ing medications in randomized clinical trials across a broad range of CVD risk and SBP levels.
It should be noted that this is a proof-of-principle study. The results of the two strategies
will, by design, appear to converge at the upper and lower ends of the CVD risk and SBP distri-
butions that are determined by the composition of this sample and findings at the ends of the
distributions are uncertain. Therefore, although the results of the present study illustrate the
Fig 3. Performance of CVD risk and SBP treatment strategies in subgroups defined at baseline. Estimates
represent differences in areas under the curve between CVD risk and SBP treatment strategies for the number of
cardiovascular events avoided per persons treated in each subgroup, defined at baseline. Bias-corrected 95% bootstrap
CIs from 10,000 repetitions in parentheses. Heterogeneity for the dataset determined for meta-analyses of two
complementary strata at a time was assessed using I2 and corresponding 95% CIs. BP, blood pressure; CI, confidence
interval, CVD, cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.g003
Blood pressure treatment based on risk versus blood pressure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002538 March 20, 2018 11 / 20
principle that a CVD risk strategy outperforms an SBP strategy over a broad range of SBPs and
CVD risks, there is a need for further studies elucidating the differences between these two strat-
egies at the lower ends of the blood pressure and CVD risk distributions, particularly because
these are values that are taken into consideration when discussing thresholds for therapeutic
intervention. The Systolic Blood Pressure Intervention Trial (SPRINT) and the Heart Outcomes
Prevention Evaluation-3 (HOPE-3) study provide data that complement our analyses and sup-
port these results [32,33]. In SPRINT, blood pressure reduction in a high-risk group (annual
event rate of 2.2%/y) below conventional targets led to a 25% reduction in cardiovascular events
and a 27% reduction in all-cause deaths [32]. In contrast, HOPE-3 did not demonstrate a car-
diovascular benefit from blood pressure reduction in a lower-risk group (annual event rate
0.8%/y) where the majority of participants had SBP below conventional targets [33].
In subgroup analyses, we found no evidence of a benefit for a CVD risk strategy compared
with SBP strategy in patients with diabetes mellitus or existing CVD. This may reflect that
“high risk” is already captured in these groups, independent of the predicted CVD risk esti-
mate. In addition, the relatively weaker performance of CVD risk prediction among persons
with existing CVD could also be explained by phenomena like index event bias [34] or obser-
vations that consequences of a cardiovascular event are often stronger predictors of a subse-
quent event than traditional risk factors [35–37]. Given the more uniformly high-risk status of
persons with prevalent CVD or diabetes mellitus, a “treat-all” strategy may be better than selec-
tive treatment based on predicted CVD risk or blood pressure level. Thus, utilizing predicted
CVD risk to guide treatment decisions may be best suited in primary prevention for individu-
als without diabetes mellitus or CVD where baseline risks and expected benefits from blood
Fig 4. Achieved SBP reduction according to CVD risk and SBP treatment strategies. Achieved SBP reduction as a
function of number of persons and proportion of sample treated using a CVD risk strategy (in green) and an SBP
strategy (in red). Numbers associated with each curve represent the specific CVD risk level (percentage 5-y CVD risk)
or SBP (mmHg) at the treatment threshold. CVD, cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.g004
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pressure-lowering treatment are more heterogeneous. This study, therefore, provides clinical
guidance for treatment decisions in a broad segment of the general population.
Clinical implications
Our results support the use of absolute risk assessment in guiding blood pressure-lowering
treatment decisions. Although risk-based treatment has been a cornerstone of cholesterol
management [9,10], blood pressure treatment guidelines like those from the US have histori-
cally emphasized blood pressure thresholds and targets [1,38]. The present study challenges
this paradigm and instead highlights the merits of using predicted CVD risk to guide intensity
of blood pressure-lowering with medications, a framework recently embraced by the 2017
American College of Cardiology (ACC)/American Heart Association (AHA) Hypertension
guidelines [39]. The limited trial experience with treatment to SBP below 120 mmHg necessar-
ily limits the scope of an entirely risk-based treatment strategy. Nevertheless, our results sup-
port the principle that treatment decisions that are based on absolute CVD risk compared with
blood pressure alone are superior for identifying persons with the highest expected benefit
from blood pressure-lowering treatment, especially in primary prevention. This assessment
can form the basis for a shared clinician–patient discussion to contextualize expected benefits
and harms of blood pressure treatment with individual values and preferences to personalize
treatment decisions.
Fig 5. Relative risk reductions by blood pressure-lowering treatment, according to CVD risk and SBP treatment
strategies. Hazard ratios of major cardiovascular events by blood pressure-lowering treatment, as a function of
number of persons and proportion of sample treated using a CVD risk strategy (in green) and an SBP strategy (in red).
Numbers associated with each curve represent the specific CVD risk level (percentage 5-y CVD risk) or SBP (mmHg)
at the treatment threshold. Hazard ratios determined from persons above each treatment threshold. CVD,
cardiovascular disease; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002538.g005
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Strengths and limitations
A key strength of this analysis is the use of a high-quality dataset of persons who were actually
treated with blood pressure-lowering medications as part of a randomized clinical trial with
rigorous follow-up and adjudicated outcomes (S5 Fig). Furthermore, our calculation of relative
risk reductions from blood pressure-lowering treatment at each potential threshold preserves
the randomized structure of the trials and maximizes the information within this dataset.
There are, however, important limitations to acknowledge in this analysis. First, most trial par-
ticipants were hypertensive at baseline, were receiving background blood pressure-lowering
therapy, and had an estimated 5-y CVD risk greater than 5%. Therefore, the majority of the
difference between the two strategies was seen among participants with SBP 150 to 170 mmHg
or 5-y CVD risk 7.5% to 15%. As such, we were unable to detect a difference between the two
treatment strategies at a 5-y CVD risk level of less than 5% or at an SBP threshold of 140
mmHg. The inability of this method to provide information at the ends of the risk and blood
pressure distributions motivates future studies in other samples that include individuals with
lower blood pressures or risk. Second, trials were of relatively short duration, and therefore,
these results do not account for the potential long-term benefits (or harms) of sustained blood
pressure management over the course of a lifetime [40]. Third, the utility of a CVD risk strat-
egy depends on the performance of the prediction algorithm employed. For this study, we
chose a previously validated, internally derived prediction algorithm to optimize model perfor-
mance. Thus, these results have high internal but unknown external validity. To account for
this limitation, we performed sensitivity analyses using the Framingham total CVD risk equa-
tion. The results, while qualitatively similar, had a lower area under the curve, suggesting
worse performance of the CVD risk strategy using an externally derived prediction algorithm.
It should be noted that modifying the used risk equation to prediction of 10- instead of 5-y
risks would yield the same ranking of participants and hence produce the same relative results.
Finally, this is a post-hoc analysis of data from clinical trials that had different objectives and
entry criteria and with numerical results driven by the composition of the study sample.
Therefore, prospective validation in a new trial would be the ideal way to confirm our findings,
but given the large number of participants required, such a trial is unlikely to be performed.
These limits notwithstanding, these results should serve as a proof of principle of the relative
merits of a CVD risk blood pressure treatment strategy in a high-quality dataset of persons
treated with blood pressure-lowering medications.
Conclusion
In conclusion, this individual participant data analysis of blood pressure-lowering trial partici-
pants supports the principle that a treatment strategy based on predicted CVD risk, compared
with one based on SBP levels, would result in prevention of more cardiovascular events for the
same number of treated persons across a wide range of potential treatment thresholds. These
results support use of cardiovascular risk assessment to guide blood pressure-lowering treat-
ment decision-making in moderate- to high-risk individuals, especially in primary prevention
settings.
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S1 Fig. Observed versus expected 5-y risks of cardiovascular events in prespecified sub-
groups. Calibration of the internally derived CVD risk prediction equation in the prespecified
subgroups. CVD, cardiovascular disease.
(PDF)
S2 Fig. Effects of CVD risk and SBP treatment strategies on absolute number of cardiovas-
cular events prevented, standardized to a 5-mmHg SBP reduction. Expected cardiovascular
events avoided over 5 y as a function of number of persons and proportion of sample treated
using a CVD risk strategy (in green) and an SBP strategy (in red), standardized to a 5-mmHg
SBP reduction. Numbers associated with each curve represent the specific CVD risk level (per-
centage 5-y CVD risk) or SBP (mmHg) at the treatment threshold. Areas under the curve are
expressed as the ratio of the obtained area to the maximum possible area (maximum number
of cardiovascular events avoided multiplied by the maximum number of persons treated) with
bias-corrected 95% bootstrap CIs from 10,000 repetitions in parentheses. Larger areas repre-
sent more avoidable events avoided per persons treated. CI, confidence interval; CVD, cardio-
vascular disease; SBP, systolic blood pressure.
(PDF)
S3 Fig. Numbers needed to treat for 5 y to avoid 1 cardiovascular event according to CVD
risk and SBP treatment strategies, standardized to a 5-mmHg SBP reduction. Numbers
needed to treat for 5 y to avoid 1 cardiovascular event as a function of number of persons and
proportion of sample treated using a CVD risk strategy (in green) and an SBP strategy (in red),
standardized to a 5-mmHg SBP reduction. Numbers associated with each curve represent the
specific CVD risk level (percentage 5-y CVD risk) or SBP (mmHg) at the treatment threshold.
CVD, cardiovascular disease; SBP, systolic blood pressure.
(PDF)
S4 Fig. Effects of CVD risk–, SBP-, and age-based treatment strategies on absolute number
of cardiovascular events prevented. Expected cardiovascular events avoided over 5 y as a
function of number of persons and proportion of sample treated using a CVD risk strategy (in
green), an SBP strategy (in red), and an age-based strategy (in blue). Numbers associated with
each curve represent the specific CVD risk (percentage 5-y CVD risk), SBP (mmHg), or age
(y) level at that treatment threshold. CVD, cardiovascular disease; SBP, systolic blood pressure.
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S5 Fig. Flow chart.
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(PREVENT [Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial]), J.
Chalmers (ADVANCE[Action in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation]), J. Cutler (ALLHAT [Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial]), B. Davis (ALLHAT), R. Estacio (ABCD [Appropriate
Blood Pressure Control in Diabetes]), R. Fagard (SYST-EUR [SYSTtolic Hypertension in
EURope]), K. Fox (EUROPA [European trial on Reduction Of cardiac events with Perindopril
among patients with stable coronary Artery disease]), T. Fukui (CASE-J [Candesartan Antihy-
pertensive Survival Evaluation in Japan]), Y. Imai (HOMED-BP [Hypertension Objective
Treatment Based on Measurement by Electrical Devices of Blood Pressure]), R. Holman
(UKPDS [UK Prospective Diabetes Study]), M. Ishii (JATOS [Japanese Trial to Assess Optimal
Systolic Blood Pressure in Elderly Hypertensive Patients], JMIC-B [Japan Multicenter Investi-
gation for Cardiovascular Diseases-B]), S. Julius (VALUE), Y. Kanno (ECOST [The Effective-
ness and Cost of ICD follow-up Schedule with Telecardiology]), S. Kjeldsen (VALUE, LIFE
[Losartan Intervention For Endpoint reduction in hypertension]), K. Kuramoto (NICS-EH
[National Intervention Cooperative Study in Elderly Hypertensives]), J. Lanke (STOP2 [Swed-
ish Trial in Old Patients with Hypertension-2], NORDIL [Nordic Diltiazem]), E. Lewis (IDNT
[Irbesartan Diabetic Nephropathy Trial]), M. Lievre (DIABHYCAR [Non-insulin-dependent
diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril
study]), L. H. Lindholm (CAPPP [Captopril Prevention Project], STOP2, NORDIL), L.
Lisheng (FEVER [Felodipine Event Reduction]), J. Lubsen (ACTION [A Coronary disease
Trial Investigating Outcome with Nifedipine GITS]), S. Lueders (MOSES [The Morbidity and
Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention]),
E. Malacco (SHELL [Systolic Hypertension in the Elderly: Lacidipine Long-Term study]), G.
Mancia (SHELL), S. MacMahon (ADVANCE), M. Matsuzaki (COPE [The Combination
Therapy of Hypertension to Prevent Cardiovascular Events]), M. Mehlum (VALUE), S. Nissen
(CAMELOT [Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis]),
H. Ogawa (HIJ-CREATE), T. Ogihara (CASE-J), T. Ohkubo (HOMED-BP), C. Palmer
(INSIGHT), A. Patel (ADVANCE), C. Pepine (INVEST [International Verapamil SR-Trando-
lapril Study]), M Pfeffer (PEACE [Prevention of Events With Angiotensin- Converting
Enzyme Inhibition]), B. Pitt (QUIET [QUinapril Ischemic Event Trial]), N. R. Poulter
(ASCOT [Anglo-Scandinavian Cardiac Outcomes Trial]), H. Rakugi (VALISH/CASE-J), G.
Remuzzi (BENEDICT [BErgamo NEphrologic DIabetes Complications Trial]), P. Ruggenenti
(BENEDICT), T. Saruta (CASE-J), J. Schrader (MOSES), R. Schrier (ABCD), P. Sever
(ASCOT), P. Sleight (CONVINCE, HOPE [Heart Outcomes Prevention Evaluation], TRAN-
SCEND [Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardio-
vascular Disease], ONTARGET [Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial]), J. Staessen (SYST-EUR [Systolic Hypertension in Europe]),
H. Suzuki (ECOST [Efficacy of Candesartan on Outcome in Saitama Trial]), K. Teo (SCAT
[Simvastatin/Enalapril Coronary Atherosclerosis Trial]), L. Thijs (Syst-Eur), K. Ueshima
(VALISH/CASE-J), S. Umemoto (COPE), W. H. van Gilst (PREVEND-IT/Renal analyses), P.
Verdeccia (Cardio-Sis), G. Viberti (ROADMAP [Randomised Olmesartan and Diabetes
Microalubuminuria Prevention]), J. Wang (NICOLE [NIsoldipine in COronary artery disease
in LEuven]), L. Wing (ANBP2 [The Second Australian National Blood Pressure Study]), Y.
Yui (JMIC-B), S. Yusuf (HOPE, ONTARGET, TRANSCEND), A. Zanchetti (SCOPE [Study
on COgnition and Prognosis in the Elderly], VHAS [Verapamil in Hypertension and
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Atherosclerosis Study], ELSA [European Lacidipine Study on Atherosclerosis], HOT [Hyper-
tension Optimal Treatment]).
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Turnbull.
The views expressed in this article are those of the authors and do not necessarily represent
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United States Department of Health and Human Services.
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